A new cancer drug candidate has demonstrated the ability to block tumor growth without triggering a common and debilitating ...

Imagine a drug that halts cancer without side effects or risks. That future may be a bit nearer thanks to recent research led ...

Revumenib for relapsed/refractory acute leukemias with KMT2A translocation is cost-neutral for health plans, but traditional ...

John Mascarenhas, MD, discusses phase 1 data showing that INCA33989 is a well-tolerated therapy for calreticulin–mutant essential thrombocythemia, with early signs of efficacy and potential disease ...